Efficacy and safety of apremilast for 3 months in Behçet's disease: A prospective observational study.

Lisa HiraharaYohei KirinoYutaro SoejimaMitsuhiro TakenoKaoru Takase-MinegishiRyusuke YoshimiMasaki TakeuchiNobuhisa MizukiHideaki Nakajima

Published in: Modern rheumatology (2020)

Significant improvement in oral ulcer and BDCAF with apremilast was confirmed in real-world BD patients after 3 months. The combination of colchicine and apremilast appears to be well tolerated in BD in the short-term.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
patient reported